Literature DB >> 36118536

Radiographic Progression and Survival of the Different HRCT Patterns of Idiopathic Pulmonary Fibrosis.

Marco Mura1, Carlotta Rellini2, Nada Taha1, Francesco Paolo Sbordone2, Flavia Rufi2, Francesca Montesanto2, Roberto Floris2, Maurizio Zompatori1, Gianluigi Sergiacomi2.   

Abstract

Introduction: Idiopathic pulmonary fibrosis (IPF) is a chronic disease with a peculiar (typical) HRCT pattern, but biopsy can demonstrate usual interstitial pneumonia in patients with atypical patterns. It is unknown how progression pattern varies among different radiographic presentations of IPF. We sought to investigate the longitudinal radiographic evolution and survival of typical and non-typical patterns. Materials and
Methods: One-hundred-twenty-three patients diagnosed with IPF in 2 tertiary referral hospitals were included in the study. Longitudinal evolution of non-typical patterns was considered. The HRCT visual fibrosis score was used as a reliable evaluation tool of disease progression. HRCTs were scored by 2 senior chest radiologists with ILD expertise. The primary endpoint was the evolution of the presentation pattern to probable or typical. The secondary endpoint was lung transplant (LTx)-free survival from the time of diagnosis.
Results: Average interval between HRCTs was 16±5 months; average follow-up after the 2nd HRCT was 17±11 months. Four out of 45 (8.9%) patients with probable pattern "evolved" to a typical pattern of IPF, while 5 out of 31 (16.1%) with indeterminate/alternative pattern "evolved" to probable pattern. An average HRCT fibrosis score increase of 9±11% was observed with typical (n=49), 6±5% with probable (n=43) and 7±8% (n=31) with indeterminate/alternative presentation pattern. LTx-free survival and lung function declines did not show any difference related to presentation HRCT patterns. Conclusions: The evolution of a non-typical UIP pattern to a typical one is infrequent. All presentation HRCT patterns of IPF evolve in similar way and are associated with comparable survival time.[/sc].

Entities:  

Keywords:  fibrosis score; high-resolution chest CT scan; idiopathic pulmonary fibrosis; progressio; usual interstitial pneumonia

Year:  2022        PMID: 36118536      PMCID: PMC9437754          DOI: 10.36141/svdld.v39i2.12534

Source DB:  PubMed          Journal:  Sarcoidosis Vasc Diffuse Lung Dis        ISSN: 1124-0490            Impact factor:   1.803


  24 in total

1.  Predicting survival in newly diagnosed idiopathic pulmonary fibrosis: a 3-year prospective study.

Authors:  Marco Mura; Maria A Porretta; Elena Bargagli; Gianluigi Sergiacomi; Maurizio Zompatori; Nicola Sverzellati; Amedeo Taglieri; Fabrizio Mezzasalma; Paola Rottoli; Cesare Saltini; Paola Rogliani
Journal:  Eur Respir J       Date:  2012-01-12       Impact factor: 16.671

Review 2.  The Value of a Multidisciplinary Approach to the Diagnosis of Usual Interstitial Pneumonitis and Idiopathic Pulmonary Fibrosis: Radiology, Pathology, and Clinical Correlation.

Authors:  Jonathan H Chung; David A Lynch
Journal:  AJR Am J Roentgenol       Date:  2016-03       Impact factor: 3.959

3.  Interobserver variability in the CT assessment of honeycombing in the lungs.

Authors:  Takeyuki Watadani; Fumikazu Sakai; Takeshi Johkoh; Satoshi Noma; Masanori Akira; Kiminori Fujimoto; Alexander A Bankier; Kyung Soo Lee; Nestor L Müller; Jae-Woo Song; Jai-Soung Park; David A Lynch; David M Hansell; Martine Remy-Jardin; Tomás Franquet; Yukihiko Sugiyama
Journal:  Radiology       Date:  2012-12-06       Impact factor: 11.105

4.  Texture-Based Automated Quantitative Assessment of Regional Patterns on Initial CT in Patients With Idiopathic Pulmonary Fibrosis: Relationship to Decline in Forced Vital Capacity.

Authors:  Hyo Jung Park; Sang Min Lee; Jin Woo Song; Sang Min Lee; Sang Young Oh; Namkug Kim; Joon Beom Seo
Journal:  AJR Am J Roentgenol       Date:  2016-08-17       Impact factor: 3.959

5.  Idiopathic Pulmonary Fibrosis: The Association between the Adaptive Multiple Features Method and Fibrosis Outcomes.

Authors:  Margaret L Salisbury; David A Lynch; Edwin J R van Beek; Ella A Kazerooni; Junfeng Guo; Meng Xia; Susan Murray; Kevin J Anstrom; Eric Yow; Fernando J Martinez; Eric A Hoffman; Kevin R Flaherty
Journal:  Am J Respir Crit Care Med       Date:  2017-04-01       Impact factor: 21.405

6.  Does technetium-99m diethylenetriaminepentaacetate clearance predict the clinical course of idiopathic pulmonary fibrosis?

Authors:  Marco Mura; Gelorma Belmonte; Stefano Fanti; Angela Maria Grazia Pacilli; Luca Fasano; Maurizio Zompatori; Mario Schiavina; Mario Fabbri
Journal:  Can Respir J       Date:  2004-10       Impact factor: 2.409

7.  Associated Pulmonary Hypertension Is an Independent Contributor to Exercise Intolerance in Chronic Fibrosing Interstitial Pneumonias.

Authors:  David K Yoo; Maurizio Zompatori; Annapina Barrile; Giorgia Rossi; Dejanira D'Amato; Gianluigi Sergiacomi; Paola Rogliani; Marco Mura
Journal:  Respiration       Date:  2018-08-16       Impact factor: 3.580

Review 8.  Clinical course and prediction of survival in idiopathic pulmonary fibrosis.

Authors:  Brett Ley; Harold R Collard; Talmadge E King
Journal:  Am J Respir Crit Care Med       Date:  2010-10-08       Impact factor: 21.405

9.  Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia.

Authors:  Kevin R Flaherty; Jeanette A Mumford; Susan Murray; Ella A Kazerooni; Barry H Gross; Thomas V Colby; William D Travis; Andrew Flint; Galen B Toews; Joseph P Lynch; Fernando J Martinez
Journal:  Am J Respir Crit Care Med       Date:  2003-05-28       Impact factor: 21.405

10.  Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline.

Authors:  Ganesh Raghu; Martine Remy-Jardin; Jeffrey L Myers; Luca Richeldi; Christopher J Ryerson; David J Lederer; Juergen Behr; Vincent Cottin; Sonye K Danoff; Ferran Morell; Kevin R Flaherty; Athol Wells; Fernando J Martinez; Arata Azuma; Thomas J Bice; Demosthenes Bouros; Kevin K Brown; Harold R Collard; Abhijit Duggal; Liam Galvin; Yoshikazu Inoue; R Gisli Jenkins; Takeshi Johkoh; Ella A Kazerooni; Masanori Kitaichi; Shandra L Knight; George Mansour; Andrew G Nicholson; Sudhakar N J Pipavath; Ivette Buendía-Roldán; Moisés Selman; William D Travis; Simon Walsh; Kevin C Wilson
Journal:  Am J Respir Crit Care Med       Date:  2018-09-01       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.